Q2 2025 Novartis AG Earnings Call Transcript
Key Points
- Novartis AG (NVS) reported double-digit sales growth of 11% in constant currency for Q2 2025.
- Core operating income increased by 21% in constant currency, reflecting strong financial performance.
- The company upgraded its full-year 2025 bottom line guidance, indicating confidence in continued growth.
- Key brands like Kisqali, Kesimpta, and Pluvicto showed robust growth, with Kisqali achieving 64% growth in the quarter.
- A new $10 billion share buyback program was announced, demonstrating strong cash flow and commitment to returning capital to shareholders.
- Cosentyx growth moderated to 6% in Q2, with challenges from new competitor entries and geographic-specific headwinds.
- The company faces potential impacts from US generic entry for Entresto, which could affect future sales.
- There is a slowdown in pharmaceutical spending in China, impacting growth for certain products like Cosentyx and Entresto.
- The competitive environment in the US remains challenging, particularly with Medicare Part D redesign affecting rebates.
- Uncertainties remain regarding the resolution of US drug pricing reforms, which could impact future pricing strategies.
Good morning and good afternoon,, and welcome to the Novartis Q2 2025 Results Release Conference Call and Live Webcast. (Operator Instructions). The conference is being recorded. (Operator Instructions). A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends.
With that, I would like to hand over to Ms. Sloan Simpson, Head of Investor Relations. Please go ahead, madam.
Thank you, Sharon. Good morning and good afternoon, everyone, and welcome to our Q2 2025 earnings call.
The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors. These may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. For a description of some of these factors, please refer to Form 20-F and its most recent quarterly results on Form 6-K that respectively were filed with
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
